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Abstract 
Purpose: To evaluate the hypoglycaemic activity of the ethanol extract, chloroform fraction, and three 
compounds isolated from Premna latifolia. 
Methods: The ethanol extract, chloroform fraction, and compounds 1 – 3 (isolated from the chloroform 
fraction) of P. latifolia were characterised by nuclear magnetic resonance (1H NMR, 13C NMR and 2D 
NMR). In vitro activity was assessed by α-amylase and α-glucosidase inhibitory activity assays. In vivo 
antidiabetic activity was evaluated in a streptozotocin-nicotinamide-induced rat model of diabetes. 
Fasting blood glucose (FBG), glycosylated haemoglobin (HbA1C), serum creatinine, blood urea nitrogen 
(BUN), liver enzymes, and antioxidant enzymes were determined. Liver and pancreas histopathology 
was assessed. 
Results: Compounds 2 and 3 exhibited significant hypoglycaemic activity by reducing elevated FBG 
and HbA1C (p ≤ 0.001) and also exerted positive effects on blood and liver enzyme profiles, which were 
largely altered in diabetic control group. These compounds also showed significant antioxidant activity, 
increasing catalase, superoxide dismutase, and glutathione reductase, while lowering malondialdehyde 
(p ≤ 0.001). The histopathology results for the rats that received these compounds suggested 
regeneration of pancreatic β-cells.  
Conclusion: Compounds 2 and 3 isolated from the dried roots of P. latifolia possess significant 
hypoglycaemic activity, reno- and hepatoprotective effects, and antioxidant activity. They show promise 
as potential treatments for patients with diabetes. 
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Diabetes mellitus is often considered the most 
important worldwide chronic disease of the 21st 
century. It is characterised by high blood glucose 
levels, which lead to substantial mortality and 
morbidity. The ultimate goals of all antidiabetic 
treatment are to first lower the blood glucose, 
then to reduce the risk of further hyperglycaemic 
episodes and lower the risk of cardiovascular 
disease, focusing on hypertension and 
dyslipidemia control [1].  
-----------------------------------------------------------------------------------------------------------------------------------------------------
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Prevailing management strategies combine 
lifestyle modifications with exercise and the use 
of oral hypoglycaemic or insulin therapy, if 
needed. However, current oral hypoglycaemic 
medications have potential side effects, such as 
weight gain, gastrointestinal symptoms, 
hematologic adverse effects, and liver or kidney 
dysfunction. They may also increase free radical 
levels. Medicinal herbs are becoming 
increasingly used as more people seek relatively 
safe remedies [2]. Exploring these natural 
products through pharmacologic experiment-
tation, including modification and derivatization, 
represents a major strategy for developing new 
drugs.  
 
Belonging to the family Verbenaceae, Premna 
latifolia is a small bushy tree 20-25 feet tall found 
across Peninsular India, Bihar, West Bengal, and 
Northeastern India. It is known as Agnimantha in 
Sanskrit, Bakar in Hindi, Erumaimunnai in Tamil, 
and Knappa in Malayalam [3]. The rough, dark 
grey bark contains branchlets with green, 
cordate, simple, opposite leaves with an 
unpleasant and characteristic odour. The roots 
are woody, branched, thick, and cylindrical, 
whereas the bisexual flowers are creamish white 
to yellowish green. The fruits are tuberculate and 
glabrous. The leaves and tender shoots are 
eaten in curries and used to treat various 
ailments, such as fever and liver symptoms. The 
leaves are also used for their diuretic, 
cardiotonic, anticoagulant, and hepatoprotective 
effects [4]. Two novel icetexane diterpenes and 
two new glycosides have been successfully 
isolated from P. latifolia [5,6].  
 
As part of continuing efforts directed towards the 
discovery of biologically active compounds from 
Indian medicinal plants, this study was conducted 
to explore the in vitro and in vivo antidiabetic 




Extraction, fractionation, and isolation from 
plant material 
 
Coarsely powdered dried roots of P. latifolia (5 
kg) were subjected to Soxhlet extraction with 
absolute ethanol (50 L). The extract was then 
concentrated. Gradient elution was performed by 
column chromatography using toluene, 
chloroform, ethyl acetate, and methanol in 
varying proportions on silica gel G (60-120), 
which was activated at 110 °C for 1 hour. The 
fractions were collected separately and 
combined based on their thin layer 
chromatography (TLC) pattern. Individual 
compounds were further purified separately by 
rechromatography using preparative TLC on 
silica gel G (for TLC) in the presence of 
toluene:ethylacetate (9.3:0.7) as the mobile 
phase.  
 
Evaluation of in vitro antidiabetic activity 
 
The α-amylase and α-glucosidase inhibitory 
activities of the ethanol extract were determined 
using the standard procedures of Unnikrishnan et 
al [7] and Jie et al [8], respectively, with minor 
modifications. IC50 was defined as the 
concentration of extract necessary to inhibit 50 % 
of the α-amylase or α-glucosidase activity under 
the assay conditions. The results are reported as 
IC50 ± standard error of the mean (SEM). 
 
Determination of in vivo antidiabetic activity 
 
Experiments assessing in vivo antidiabetic 
activity were approved by our Institutional Animal 
Ethics Committee (approval ref no.-
RGIP/03/2012) and based on the Committee for 
the Purpose of Control and Supervision of 
Experiment on Animals guidelines [9]. The study 
was conducted in accordance with the rules and 
regulations of our Institutional Animal Ethics 
Committee. Healthy adult Wister rats of both 
sexes (weighing 150 – 180 g) were selected for 
the study. The rats were kept in clean 
polypropylene cages and maintained at local 
animal house conditions: temperature 24 ± 2 °C, 
humidity 45 ± 5 %, and 12-h day/12-h night cycle 
[10]. The animals were fed a standard pellet diet 
(Sai Durga Feeds and Foods, Bangalore, India), 
and water was available ad libitum.  
 
The rats were divided into 8 groups of 6 rats 
each. Group I served as normal control, whereas 
Group II was the diabetic control; both groups 
were given 1 mg/kg of 0.5 % sodium 
carboxymethyl cellulose. Group III, the standard 
treatment group, was given glibenclamide (5 
mg/kg), whereas Group IV and V were 
administered ethanolic extracts of P. latifolia 
(PLE) or chloroform fraction (PLF) at doses of 
200 mg/kg and 100 mg/kg, respectively. Group 
VI was treated with compound 1 (PL1), Group VII 
was given compound 2 (PL2), and Group VIII 
was administered compound 3 (PL3) (15 mg/kg 
for PL1 – PL3). 
 
The rats were fasted overnight before the 
experiments. They underwent intraperitoneal 
administration of 110 mg/kg nicotinamide in 
normal physiological saline, followed 15 minutes 
later by a freshly prepared solution of 
streptozotocin dissolved in 0.1 M citrate buffer 
pH 4.5 at a dose of 60 mg/kg [11-12]. Seventy-
two hours after streptozotocin injection, the blood 
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glucose level of each rat was measured, and rats 
with a fasting blood glucose (FBG) level above 
250 mg/dL were considered diabetic and used 
for this investigation [13]. One hour after 
administration of the control solution (sodium 
carboxymethyl cellulose), standard treatment 
(glibenclamide), or experimental treatment (PLE, 
PLF, PL1, PL2, or PL3), blood samples were 
collected using tail vein puncture technique 
under light anaesthesia to determine FBG level. 
FBG was determined by the glucose oxidase 
method, using a commercially available 
biochemical kit (Roche Diabetes Care India Pvt 
Ltd., Mumbai, India). The treatments were 
repeated daily for the next 28 days, and FBG 
levels were determined on days 0, 14, and 28. 
On day 28, the rats were sacrificed, and the liver 
and pancreas were removed for histopathology 
studies [14-15]. Other biochemical parameters, 
including the levels of antioxidant enzymes, were 




The pancreatic and liver samples of all rats were 
removed and placed in 10 % formalin buffer 
solution. A small piece of tissue was sectioned 
with a microtome, fixed onto slides, stained with 
hematoxylin and eosin dye (H&E) and observed 
under an optical microscope.  
 
Blood biochemical parameters analysis 
 
FBG, glycosylated haemoglobin (HbA1C), serum 
creatinine, blood urea nitrogen (BUN), serum 
glutamic oxaloacetic transaminase (SGOT), 
serum glutamic pyruvic transaminase (SGPT), 
alkaline phosphatase (ALP), catalase (CAT), 
superoxide dismutase (SOD), malondialdehyde 
(MDA), and glutathione reductase (GSH) were 




The data are expressed as mean ± SEM. One-
way ANOVA, followed by Tukey's multiple 
comparisons test, was performed. All statistical 
analyses were conducted using the GraphPad 
Prism 5 statistical package (Graph Pad Software, 
USA). Comparisons with a p value ≤ 0.001 were 




The three new compounds isolated from the dried 
roots of P. latifolia, designated as compounds 1 – 
3, are shown in Figure 1.  
 
 




(compound 2)    
 
n-tetracosanol (compound 3) 
 
Figure 1: Structure of three compounds isolated from 
the dried roots of P. latifolia 
 
In vitro antidiabetic activity 
 
As glucose-lowering medications, α-amylase and 
α-glucosidase inhibitors delay the absorption of 
ingested carbohydrates, reducing postprandial 
glucose and insulin peaks. The ethanolic extract 
exhibited significant inhibition of α-glucosidase 
and α-amylase, with IC50 values of 84.57 µg/mL 
and 96.33 µg/mL, respectively. These effects 
were dose-dependent, as shown in Table 1 and 
Table 2. Acarbose, which was used as the 
positive control, had IC50 values of 72.30 µg/mL 
for α-glucosidase and 88.10 µg/ml for α-amylase, 
under similar assay conditions. These results 
reveal the in vitro antidiabetic activity of P. 
latifolia root extract. 
 
Table 1: Inhibitory potency of Premna latifolia root 
extract against α-glucosidase and α-amylase 
 
Ethanol extract  IC50 (µg/mL) 
α-Glucosidase inhibitory activity  







α-glucosidase inhibitory activity  




Values are mean ± SEM (n = 3). a p ≤ 0.001 vs. 
standard. 
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Effect of Premna latifolia on fasting blood 
glucose levels 
 
Administration of streptozotocin causes 
widespread β-cell destruction in the pancreas via 
DNA strand breakage, leading to 
hyperglycaemia. After 28 days, no significant 
change in blood glucose was noted in normal 
rats, whereas blood glucose levels were 
significantly increased in diabetic rats. Treatment 
with the ethanolic extract and chloroform fraction 
of P. latifolia produced a slight reduction in 
elevated FBG. Chloroform fraction at a dose of 
100 mg/kg was most effective, producing a 19.40 
% decrease in elevated FBG levels on the last 
day. In rats administered compound 2 at a dose 
of 15 mg/kg, there was a dynamic decrease in 
FBG levels to a maximum decrease of 48.42 % 
decrease by day 28, which was a significantly 
greater change than for the diabetic control 
group (p ≤ 0.001; Table 2).  
 
Compound 1 showed no significant effects, but 
administration of compound 3 produced a time-
dependent reduction in FBG levels to a 
maximum decrease of 33.71 % by day 28. Thus, 
these results demonstrate that compounds 2 and 
3 have prominent antihyperglycemic effect. 
 
Effect of Premna latifolia on HbA1C, 
creatinine, and BUN 
 
HbA1C, formed by non-enzymatic glycation 
pathway in response to plasma glucose, is 
considered an indicator of the onset of diabetes 
mellitus and the degree of glucose control over 
time. HbA1C levels were increased to 13.10 % in 
diabetic control rats on day 28, and both the 
ethanolic extract and chloroform fraction 
produced significantly lower HbA1C levels. 
Compounds 2 and 3 significantly lowered HbA1C 
on day 28 to 5.11 % and 6.12 %, respectively; 
these levels were close to those seen with 
standard treatment. Creatinine and BUN, two 
major biomarkers of renal dysfunction, increased 
to 1.60 mg/dL and 90.30 mg/dL, respectively, on 
day 28 in the diabetic control group. The PLE 
and PLF groups had significantly lower creatinine 
and BUN levels than the diabetic control group, 
but compound 1 had no effect. Compared with 
diabetic control rats, creatinine and BUN on day 
28 were lower in rats treated with compound 2 
(1.01 mg/dL and 62.80 mg/dL, respectively) (p ≤ 
0.001) and rats treated with compound 3 (1.12 
mg/dL and 67.00 mg/dL, respectively) (p ≤ 0.001; 
Table 3). 
 
Effect of Premna latifolia on liver enzyme 
levels 
 
The liver plays a major role in metabolism, 
detoxification, storage, and excretion of 
xenobiotics and their associated metabolites. In 
diabetes mellitus, liver enzymes are often raised 
secondary to enzymes leaking from the liver 
cytosol into the bloodstream; this is an indication 
of hepatotoxicity. Standard treatment of diabetic 
rats with glibenclamide reduced SGOT, SGPT, 
and ALP to 43.70 IU/L, 65.80 IU/L, and 61.20 
IU/L, respectively, on day 28. Both ethanolic 
extract and chloroform fraction exerted little 
effect, whereas rats receiving compound 2 
exhibited significantly lower levels of SGOT, 
SGPT and ALP on day 28 (50.10 IU/L, 67.10 
IU/L, and 67.00 IU/L, respectively), compared 
with diabetic control rats (p < 0.001). Compound 3 
also significantly decreased these enzymes, 
when compared to diabetic control rats, as 
shown in Table 4. Thus, compounds 2 and 3 
exerted a protective effect on the liver but 
compound 1 had no effect. 
 





Mean (mg/dL) Change in 
FBG on day 
28 (%)a Day 0  Day 14 Day 28 
Normal 80.80±0.307 83.30±0.667 82.30±0.667 +1.86 
Diabetic control 280.00±0.477a 282.00±0.792 a 301.00±0.725 a +7.50 
Diabetic+standard 264.39±0.477b 131.01±0.872b 95.70±0.577b -63.80 
Diabetic+PLE (200 mg/kg) 275.00±0365bc 244.00±0.365bc 240.00±0.333bc -12.73 
Diabetic+PLF (100 mg/kg) 268.00±0.477bc 231.00±0.307bc 216.00±0.365bc -19.40 
Diabetic+PL1 (15 mg/kg) 279.00±0.428 281.00±0.333 298.00±1.920 +6.81 
Diabetic+PL2 (15 mg/kg) 263.02±0.577bc 197.00±0.422bc 135.66±0.428bc -48.42 
Diabetic+PL3 (15 mg/kg) 264.00±0.333bc 203.02±0.422bc 175.00±0.667bc -33.71 
Values are mean ±SEM (n=6). a p ≤ 0.001 vs. normal control; b p ≤ 0.001 vs. diabetic control; c p ≤ 0.001 vs. 
standard treatment. FBG, fasting blood glucose; PL2, chloroform fraction of P. latifolia; PLE, ethanolic extract of 
P. latifolia; PL1 – PL3, compounds 1 – 3 from P. latifolia 
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Table 3: Effect of Premna latifolia on blood biochemical parameters on day 28  
 
Group HbA1C (%) Creatinine (mg/dL) BUN (mg/dL) 
Normal 3.00±0.053 0.545±0.009 43.20±0.833 
Diabetic control 13.10±0.063a 1.600±0.014a 90.30±0.882 
Diabetic+standard 4.83±0.106b 0.862±0.005b 56.70±0.667b 
Diabetic+PLE (200 mg/kg) 11.00±0.040bc 1.47±0.007bc 82.30±0.494bc 
Diabetic+PLF (100 mg/kg) 7.91±0.058bc 1.390±0.005bc 77.00±0.577bc 
Diabetic+PL1 (200 mg/kg) 12.90±0.310 1.640±0.008 89.70±0.760 
Diabetic+PL2 (15 mg/kg) 5.11±0.049bc 1.010±0.009bc 62.80±0.477bc 
Diabetic+PL3 (15 mg/kg) 6.12±0.015bc 1.120±0.006bc 67.00±0.577bc 
Values are mean ± SEM (n=6).  a p ≤ 0.001 vs. normal control; b p ≤ 0.001 vs. diabetic control; c p ≤ 0.001 vs. 
standard treatment. PL2, chloroform fraction of P. latifolia; PLE, ethanolic extract of P. latifolia; PL1 – PL3, 
compounds 1 – 3 from P. latifolia 
 
           Table 4: Effect of Premna latifolia on liver enzymes on day 28 
 
Group SGOT (IU/L) SGPT (IU/L) ALP (IU/L) 
Normal 35.60±0.050 57.90±0.028 55.20±0.010 
Diabetic control 73.60±0.033a 93.70±0.042a 87.70±0.008a 
Diabetic+standard 43.70±0.030b 65.80±0.016b 61.20±0.017b 
Diabetic+PLE (200 mg/kg) 70.90±0.033bc 88.90±0.031bc 81.70±0.013bc 
Diabetic+PLF (100 mg/kg) 64.60±0.031bc 79.70±0.023bc 77.30±0.010bc 
Diabetic+PL1(15 mg/kg) 73.80±0.579 93.60±0.452 87.50±0.273 
Diabetic+PL2 (15 mg/kg) 50.10±0.031bc 67.10±0.025bc 67.00±0.018bc 
Diabetic+PL3 (15 mg/kg) 54.30±0.018bc 67.10±0.034bc 70.30±0.012bc 
Values are mean ± SEM (n = 6); a p ≤ 0.001 vs. normal control; b p ≤ 0.001 vs. diabetic control; c p ≤ 0.001 vs. 
compared with standard treatment; ALP, alkaline phosphatase; PL2, chloroform fraction of P. latifolia; PLE, 
ethanolic extract of P. latifolia; PL1 – PL3, compounds 1 – 3 from P. latifolia; SGOT, serum glutamic oxaloacetic 
transaminase; SGPT, serum glutamic pyruvic transaminase 
 
Effect of Premna latifolia on antioxidant 
enzyme levels 
 
Much evidence indicates a strong relationship 
between diabetes mellitus and oxidative stress 
induced by free radicals, which contribute to a 
variety of diabetic complications, such as 
coronary artery disease, retinopathy, and 
nephropathy.  Studies have shown that the 
majority of plasma antioxidants are depleted in 
diabetic patients, and antioxidant therapy has 
been helpful in reducing complications of 
diabetes.  In prolonged diabetes, levels of key 
antioxidant enzymes such as CAT, SOD, and 
GSH are decreased, whereas levels of lipid 
peroxidation markers such as MDA are 
increased. 
 
CAT, SOD, and GSH were reduced in diabetic 
control rats to 52.3 nM H2O2 decomposed/ min/ 
g, 10.40 U/mg protein, and 20.80 µ mol of 
GSH/mg protein, respectively, on day 28, which 
were improved to almost normal by treatment 
with standard therapy (glibenclamide). CAT, 
SOD, and GSH levels were 69.90 nM H2O2 
decomposed/ min/ g, 16.20 U/mg protein, and 
32.10 µ mol of GSH/mg protein , respectively, in 
rats administered compound 2 and 88.60 µ mol 
of GSH/mg protein, 14.60 U/mg protein, and 31.5 
µ mol of GSH/mg protein µ mol of GSH/mg 
protein, respectively, in rats treated with 
compound 3. These values were significantly 
higher than those seen in the diabetic control 
group, although lower than those in the standard 
treatment group (p ≤ 0.001; Tables 5 and 6).  
 
In diabetes mellitus, MDA, which is produced by 
degradation of polyunsaturated lipids by free 
radicals, is increased. MDA was lower with 
compounds 2 and 3 (36.90 nmol/mL for both) 
than in diabetic control rats on day 28, as shown 
in Table 6. 
 
Effect of Premna latifolia on pancreatic and 
liver histopathology  
 
The normal group rats had a normal pancreatic 
surface, with no traces of fibrosis. However, 
diabetic control rat had extensive pancreatic 
damage, with necrosis and fibrosis. Standard 
treatment rats exhibited substantially less 
pancreatic fibrosis and atrophy than the controls. 
Groups treated with extract and fraction exhibited 
less cellular degeneration than the diabetic 
control group. Rats administered compounds 2 
and 3 exhibited significantly less fibrosis, which 
was associated with improved architecture and 
function of the pancreas (Figure 2). Compound 1 
rats exhibited no substantial improvement, 
compared with diabetic control rats. 
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Normal 78.90±0.031 20.60±0.201 39.30±0.063 
Diabetic control 52.30±0.0165a 10.40±0.312a 20.80±0.016a 
Diabetic+standard 72.70±0.016b 18.90±0.293b 34.00±0.021b 
Diabetic+PLE (200 mg/kg) 58.10±0.020bc 11.60±0.056bc 23.60±0.050bc 
Diabetic+PLF (100 mg/kg) 65.30±0.020bc 12.60±0.008bc 27.80±0.019bc 
Diabetic+PL1 (15 mg/kg) 52.90±0.317 10.60±0.100 20.90±0.436 
Diabetic+PL2 (15 mg/kg) 69.90±0.020bc 16.20±0.017bc 32.10±0.010bc 
Diabetic+PL3 (15 mg/kg) 68.60±0.023bc 14.60±0.048bc 31.50±0.676bc 
Values are mean ± SEM (n = 6); a p ≤ 0.001 vs. normal control; b p ≤ 0.001 vs. diabetic control; c p ≤ 0.001 vs. 
standard treatment; CAT, catalase; PL2, chloroform fraction of P. latifolia; PLE, ethanolic extract of P. latifolia; 
PL1 – PL3, compounds 1 – 3 from P. latifolia; SOD, superoxide dismutase 
 
Table 6: Effect of Premna latifolia on MDA and GSH 
levels on day 28 
 
Group MDA (nmol/mL) 
Normal 30.10±0.017 
Diabetic control 49.60±0.025a 
Diabetic+standard 34.00±0.013b 
Diabetic+PLE (200 mg/kg) 46.90±0.154bc 
Diabetic+PLF (100 mg/kg) 43.60±0.019bc 
Diabetic+PL1 (200 mg/kg) 48.90±0.305 
Diabetic+PL2 (15 mg/kg) 36.90±0.019bc 
Diabetic+PL3 (15 mg/kg) 36.90±0.152bc 
Values are mean ± SEM (n = 6);  a p ≤ 0.001 vs. 
normal control; b p ≤ 0.001 significant difference vs. 
diabetic control; c p ≤ 0.001 vs. standard treatment; 
GSH, glutathione reductase; MDA, malondialdehyde; 
PL2, chloroform fraction of P. latifolia; PLE, ethanolic 
extract of P. latifolia; PL1 – PL3, compounds 1 – 3 
from P. latifolia 
 
Liver samples from normal rats exhibited distinct 
lobulation with normal portal triads and central 
veins. Samples from diabetic control rats 
exhibited severe fatty changes of hepatocytes, 
with collections of inflammatory cells and 
hepatocytes. Livers from standard treatment rats 
exhibited minimal periportal fatty infiltration and 
focal necrosis of hepatocytes. Groups treated 
with extract and fraction exhibited a minimal 
percentage of hepatocytes with fatty changes (20 
– 30 %). Samples from rats treated with 
compounds 2 and 3 at a dose of 15 mg/kg had 
minimal hepatocyte damage, with less 
aggregation of inflammatory cells and 
hepatocytes and less focal necrosis (Figure 3). 
Liver samples from the compound 1 group 
showed no difference in liver architecture, when 





Figure 2: Histopathologic examination of pancreatic tissues of different experimental groups: (A) normal, (B) 
diabetic control, (C) diabetic+standard, (D) diabetic+PLE (200 mg/kg), (E) diabetic+PLF (100 mg/kg), (F) 
diabetic+PL1 (15 mg/kg), (G) diabetic+PL2 (15 mg/kg), and (H) diabetic+PL3 (15 mg/kg).  Slides were stained 
with H&E dye. Magnification: X100. PL2, chloroform fraction of P. latifolia; PLE, ethanolic extract of P. latifolia; 
PL1 – PL3, compounds 1 – 3 from P. latifolia 
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Figure 3: Histopathologic examination of liver tissues of different experimental groups: (A) normal, (B) diabetic 
control, (C) diabetic+standard, (D) diabetic+PLE (200 mg/kg), (E) diabetic+PLF (100 mg/kg), (F) diabetic+PL1 
(15 mg/kg), (G) diabetic+PL2 (15 mg/kg), and (H) diabetic+PL3 (15 mg/kg). Slides were stained with H&E dye. 
Magnification: X100.  PL2, chloroform fraction of P. latifolia; PLE, ethanolic extract of P. latifolia; PL1 – PL3, 




The present study focused on evaluating the 
hypoglycaemic activity of three compounds 
isolated from P. latifolia, along with its ethanolic 
extract and chloroform fraction. As diabetes 
mellitus is associated with various metabolic 
disturbances, we also extensively evaluated the 
effects of these substances on various blood 
biochemical parameters and histopathology of 
the pancreas and liver. 
 
First, we confirmed the in vitro antidiabetic 
activity of the ethanolic extract using α-amylase 
and α-glucosidase inhibitory assays; the extract 
produced inhibition of both assays, when 
compared with the standard acarbose. We 
subsequently used a streptozotocin-
nicotinamide-induced rat model of diabetes to 
evaluate the in vivo antidiabetic effects of the 
three isolated compounds, ethanolic extract, and 
chloroform fraction. Compound 2 (15 mg/kg) 
reduced the elevated FBG levels by 48.42 %, 
suggesting that it improved insulin secretion from 
remnant pancreatic β-cells or promoted 
regeneration of destroyed β-cells. 
Histopathologic examination of pancreatic tissue 
suggested that regeneration occurred. 
Compound 3 (15 mg/kg) also reduced FBG 
levels, albeit by a smaller amount (33.71 %). 
Similarly, administration of compounds 2 and 3 to 
diabetic rats decreased HbA1C levels from 13.10 
% (diabetic control group) to 5.11 % and 6.12 %, 
respectively, representing excellent control of the 
disease. 
 
We also studied the in vivo effects of the P. 
latifolia substances on kidney and liver function. 
Creatinine and BUN levels, as biomarkers of 
renal dysfunction, are increased with prolonged 
diabetes [17], and elevated levels were markedly 
reduced with compound 2, compared to diabetic 
controls. Compound 3 exhibited a similar 
(although less obvious) effect, clearly indicating 
that P. latifolia has renoprotective effects in 
diabetic rats. Serum levels of liver enzymes, 
representing hepatic damage, are also increased 
in diabetes mellitus [18]. Rats treated with 
ethanolic extract, chloroform fraction, and 
compounds 2 and 3 had significantly lower 
enzyme levels than diabetic control rats. Minimal 
liver damage was noted on histopathologic 
examination in rats treated with compounds 2 
and 3, in contrast to the severe changes 
observed in control diabetic rats.  
 
In diabetic patients, auto-oxidation of glucose 
leads to the production of free radicals [19]. If 
levels of free radicals exceed the scavenging 
ability of antioxidant enzymes in the body, 
harmful oxidative stress occurs [20]. In diabetes, 
levels of CAT, SOD, and GSH are reduced, while 
levels of MDA are elevated. Compound 2 
increased CAT, SOD, and GSH and decreased 
MDA. Thus, P. latifolia not only has significant 





The findings of this study demonstrate that two 
new compounds from P. latifolia, compounds 2 
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and 3, show substantial promise as potential 
therapeutic agents, exemplified by their 
significant antidiabetic activity, reno- and 
hepatoprotective effects, and antioxidant activity. 
The antioxidant property may reduce oxidative 
stress in patients with diabetes mellitus, thereby 
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